Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capivasertib - AstraZeneca

Drug Profile

Capivasertib - AstraZeneca

Alternative Names: AZD 5363

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer Astex Therapeutics; AstraZeneca; Cancer Research Technology; Conquer Cancer Foundation; Royal Marsden NHS Foundation Trust; Samsung Medical Center; The Institute of Cancer Research; University of Nottingham; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 05 Aug 2019 AstraZeneca initiates a phase I trial Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in USA (NCT04087174)
  • 07 Jun 2019 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in Spain and France (PO) (EudraCT2018-004687-64)
  • 07 Jun 2019 Phase-III clinical trials in Breast cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in Sweden (PO) (EudraCT2018-004687-64)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top